0001626199-19-000001.txt : 20190130 0001626199-19-000001.hdr.sgml : 20190130 20190130150911 ACCESSION NUMBER: 0001626199-19-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190130 DATE AS OF CHANGE: 20190130 EFFECTIVENESS DATE: 20190130 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC. CENTRAL INDEX KEY: 0001626199 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208969493 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-331755 FILM NUMBER: 19551578 BUSINESS ADDRESS: STREET 1: 201 ELLIOTT AVE. WEST, SUITE 230 CITY: SEATTLE STATE: WA ZIP: 98119 BUSINESS PHONE: 206-788-4545 MAIL ADDRESS: STREET 1: 201 ELLIOTT AVE. WEST, SUITE 230 CITY: SEATTLE STATE: WA ZIP: 98119 FORMER COMPANY: FORMER CONFORMED NAME: Nivalis Therapeutics, Inc. DATE OF NAME CHANGE: 20150211 FORMER COMPANY: FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141121 D 1 primary_doc.xml X0708 D LIVE 0001626199 ALPINE IMMUNE SCIENCES, INC. 201 ELLIOTT AVE. WEST, SUITE 230 SEATTLE WA WASHINGTON 98119 206-788-4545 DELAWARE Nivalis Therapeutics, Inc. N30 Pharmaceuticals, Inc. Corporation true James Paul Rickey 201 Elliott Avenue West, Ste 230 Seattle WA WASHINGTON 98119 Executive Officer Senior Vice President and Chief Financial Officer Mark James Litton 201 Elliott Avenue West, Ste 230 Seattle WA WASHINGTON 98119 Executive Officer President and Chief Operating Officer Mitchell Gold 201 Elliott Avenue West, Ste 230 Seattle WA WASHINGTON 98119 Executive Officer Director Executive Chairman and Chief Executive Officer Stanford Peng 201 Elliott Avenue West, Ste 230 Seattle WA WASHINGTON 98119 Executive Officer Executive Vice President of Research and Development and Chief Medical Officer Robert Conway 201 Elliott Avenue West, Ste 230 Seattle WA WASHINGTON 98119 Director Christopher Peetz 201 Elliott Avenue West, Ste 230 Seattle WA WASHINGTON 98119 Director Paul Sekhri 201 Elliott Avenue West, Ste 230 Seattle WA WASHINGTON 98119 Director Peter Thompson 201 Elliott Avenue West, Ste 230 Seattle WA WASHINGTON 98119 Director James Topper 201 Elliott Avenue West, Ste 230 Seattle WA WASHINGTON 98119 Director Jay Venkatesan 201 Elliott Avenue West, Ste 230 Seattle WA WASHINGTON 98119 Director Cui Xiangmin 201 Elliott Avenue West, Ste 230 Seattle WA WASHINGTON 98119 Director Biotechnology Decline to Disclose 06b false 2019-01-18 false true true true false 0 Piper Jaffray & Co. 665 None None 800 Nicollet Mall Minneapolis MN MINNESOTA 55402 CA CALIFORNIA IL ILLINOIS MD MARYLAND MA MASSACHUSETTS NY NEW YORK OR OREGON UT UTAH VT VERMONT WA WASHINGTON true 48660651 25274979 23385672 The Issuer sold an aggregate of 4,706,700 units to the investors at a price per unit of $5.37. Each unit consisted of one share of common stock and a warrant to purchase 0.39 of a share of common stock at an exercise price per share of $12.74. false 8 907499 75000 0 false ALPINE IMMUNE SCIENCES, INC. /s/James Paul Rickey James Paul Rickey Senior VP and CFO 2019-01-29